Global Gene Editing Beyond CRISPR Market (2022 to 2035) - Focus on Zinc Finger Nucleases, Transcription Activator-Like Effector Nucleases and Meganucleases Edited Therapies
22 mars 2022 06h13 HE
|
Research and Markets
Dublin, March 22, 2022 (GLOBE NEWSWIRE) -- The "Gene Editing beyond CRISPR Market: Focus on Zinc Finger Nucleases, Transcription Activator-Like Effector Nucleases and Meganucleases Edited Therapies:...
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia
09 mars 2022 16h01 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative...
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
28 févr. 2022 16h01 HE
|
Intellia Therapeutics, Inc.
Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levelsDurable serum TTR reductions...
Global CRISPR Market & Competition Landscape 2021-2028 Featuring Profiles of Integrated DNA Technologies, Intellia Therapeutics, Horizon Discovery Group, and Precision Biosciences Among Others
04 févr. 2022 05h38 HE
|
Research and Markets
Dublin, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The "Global CRISPR Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. The global CRISPR market is anticipated to display growth...
Outlook on the Oligonucleotide Synthesis Global Market - Featuring Abbott Diagnostics, Amyris and Bayer Among Others
03 févr. 2022 04h38 HE
|
Research and Markets
Dublin, Feb. 03, 2022 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Markets - Forecasts by Oligo Length, Application, and Product - With Executive and Consultant Guides and including Customized...
Genome Editing Market Size ($16.98Bn by 2028) Lead by CRISPR Technology (18.4% CAGR) - Exclusive Research Report by The Insight Partners
20 janv. 2022 12h48 HE
|
The Insight Partners
New York, Jan. 20, 2022 (GLOBE NEWSWIRE) -- According to our new research study on “Genome Editing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (CRISPR, TALEN,...
Global CRISPR Gene Editing Market Report 2021-2031: Opportunities in Expanding Gene and Cell Therapy Area & CRISPR Gene Editing Scope in Agriculture
14 janv. 2022 05h33 HE
|
Research and Markets
Dublin, Jan. 14, 2022 (GLOBE NEWSWIRE) -- The "CRISPR Gene Editing Market - A Global and Regional Analysis: Focus on Product, Application, End User, and Country-Wise Analysis - Analysis and...
$11.7 Bn Genome Editing/Genome Engineering Markets - Global Analysis & Forecasts to 2026
20 déc. 2021 05h28 HE
|
Research and Markets
Dublin, Dec. 20, 2021 (GLOBE NEWSWIRE) -- The "Genome Editing/Genome Engineering Market - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The global genome...
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
13 déc. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
22 nov. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced today that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has...